Established and emerging therapies for hepatocellular carcinoma

Minerva Medica

Volumn 101, Issue 6, 2010, Pages 405-418

  Cicinnati, V R ^a   Sotiropoulos, G C ^a   Beckebaum, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Carcinoma, hepatocellular; Neoplasm staging; Tumor markers, biological

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EVEROLIMUS; GEFITINIB; LAPATINIB; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ALGORITHM; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER THERAPY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG WITHDRAWAL; DRY SKIN; HAND FOOT SKIN REACTION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; LEUKOPENIA; LIVER ARTERY THROMBOSIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; THROMBOCYTOPENIA; VOICE CHANGE; WEIGHT REDUCTION; WOUND DEHISCENCE; WOUND INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; FORECASTING; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952643439     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
5. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-S37.
6. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-6.
7. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010 [Epub ahead of print].
8. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-6.
9. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67.
10. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72(Suppl 1):30-44.
11. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
12. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
13. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010;51:1284-90.
14. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86.
15. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
17. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
18. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270-85.
19. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-9.
20. Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del GM et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003;17(Suppl 2):119-29.
21. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005;201:663-70.
22. Laurent C, Blanc JF, Nobili S, Sa CA, le BB, Bioulac-Sage P et al. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005;201:656-62.
23. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007;205:27-36.
24. Sotiropoulos GC, Lang H, Frilling A, Molmenti EP, Paul A, Nadalin S et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006;53:322-9.
25. Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010 [Epub ahead of print].
26. Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000;18:1094-101.
27. Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol 2010;17:1226-33.
28. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989;209:88-98.
29. Busuttil RW, Farmer DG. The surgical treatment of primary hepatobiliary malignancy. Liver Transpl Surg 1996;2:114-30.
30. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003;21:4329-35.
31. Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl 2007;13:S36-S43.
32. Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol 2007;3:429-39.
33. Sotiropoulos GC, Beckebaum S, Lang H, Frilling A, Molmenti EP, Cicinnati VR et al. Single-center experience on liver transplantation for hepatocellular carcinoma arising in alcoholic cirrhosis: results and ethical issues. Eur Surg Res 2008;40:7-13.
34. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
35. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8:736-48.
36. Hemming AW, Cattral MS, Reed AI, Van der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-9.
37. Zavaglia C, De CL, Alberti AB, Minola E, Belli LS, Slim AO et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-16.
38. Malago M, Hertl M, Testa G, Rogiers X, Broelsch CE. Split-liver transplantation: future use of scarce donor organs. World J Surg 2002;26:275-82.
39. Malago M, Testa G, Frilling A, Nadalin S, Valentin-Gamazo C, Paul A et al. Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg 2003;238:853-62.
40. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239:142-9.
41. Malago M, Testa G, Marcos A, Fung JJ, Siegler M, Cronin DC et al. Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transpl 2001;7:921-7.
42. Kaihara S, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003;75:S37-S40.
43. Malago M, Sotiropoulos GC, Nadalin S, Valentin-Gamazo C, Paul A, Lang H et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl 2006;12:934-40.
44. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2004;10:440-7.
45. Sotiropoulos GC, Paul A, Molmenti E, Lang H, Frilling A, Napieralski BP et al. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation 2005;80:897-902.
46. Sotiropoulos GC, Lang H, Nadalin S, Neuhauser M, Molmenti EP, Baba HA et al. Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 2007;205:661-75.
47. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
48. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-5.
49. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
50. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
51. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007;25:310-2.
52. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007;83:893-9.
53. Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 2007;25:299-302.
54. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariant L et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
55. Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantatioa? - no, never. J Hepatol 2005;43:573-7.
56. Kaido T, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010;16:538-40.
57. Sotiropoulos GC, Molmenti EP, Lang H. Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer. Lancet Oncol 2009;10:207-8.
58. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-42.
59. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327-36.
60. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Morgan GR, Diflo T et al. Transplantation for hepatocellular Carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8:1156-64.
61. Lopez HE, Vogl TJ, Bechstein WO, Guckelberger O, Neuhaus P, Lobeck H et al. Biphasic spiral computed tomography for detection of hepatocellular carcinoma before resection or orthotopic liver transplantation. Invest Radiol 1998;33:216-21.
62. Sotiropoulos GC, Malago M, Molmenti E, Paul A, Nadalin S, Brokalaki E et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 2005;79:483-7.
63. Bhartia B, Ward J, Guthrie JA, Robinson PJ. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003;180:577-84.
64. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002;6:224-32.
65. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F et al. Focal lesions in cirrhotic expiant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002;8:749-61.
66. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004;78:1780-6.
67. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007;245:435-42.
68. Sotiropoulos GC, Malago M, Bockhorn M, Schmitz KJ, Radtke A, Molmenti EP et al. Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified? Hepatogastroenterology 2008;55:1671-7.
69. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
70. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-51.
71. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010,21(Suppl 5):v59-v64.
72. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73.
73. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003;226:441-51.
74. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-9.
75. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005;234:954-60.
76. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
77. Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008;15:3169-77.
78. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-61.
79. Salem R, Thurston KG. Radioembolization with 90Yt-trium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251-78.
80. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et at. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
81. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9.
82. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2010 [Epub ahead of print].
83. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-6.
84. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
85. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
86. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
87. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010;17:1247-56.
88. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010;15:285-92.
89. Zhu AX, Sahani DV, Duda DG, di TE, Ancukiewicz M, Catalano OA et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35.
90. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006;24:4143.
91. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T et at. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67.
92. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
93. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15:5895-901.
94. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777-83.
95. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581-9.
96. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ et al. Phase II trial evaluating the clinical and biologic effects of bevadzumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8.
97. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
98. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S.
99. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005;435:745-6.
100. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.